Asenapine

Asenapine
Systematic (IUPAC) name
	(3aRS,12bRS)-rel-5-Chloro-2,3,3a,12b-tetrahydro-; 2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
Clinical data
Trade names	Saphris, Sycrest
AHFS/Drugs.com	monograph
MedlinePlus	a610015
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	C (US)
Legal status	Rx only
Routes	sublingual
Pharmacokinetic data
Bioavailability	35% sublingual
Protein binding	95%
Metabolism	hepatic
Half-life	24 hours
Excretion	50% in urine, 40% in feces
Identifiers
CAS number	65576-45-6
ATC code	N05AH05
PubChem	CID 163091
IUPHAR ligand	22
ChemSpider	2300725
UNII	JKZ19V908O
ChEBI	CHEBI:71253
ChEMBL	CHEMBL1201756
Chemical data
Formula	C17H16ClNO
Mol. mass	285.77 g/mol
	SMILES Clc4cc2c(Oc1c(cccc1)[C@@H]3CN(C[C@@H]23)C)cc4;
	InChI InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1 ; Key:VSWBSWWIRNCQIJ-GJZGRUSLSA-N ;
(what is this?) (verify);

Asenapine (INN, trade names Saphris, Sycrest) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel.^[1] Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA accepted the manufacturer's NDA on November 26, 2007 for standard review.^[2]

Some American psychiatrists have begun to prescribe the drug to combat veterans with severe PTSD nightmares as an "off-label" use^{[citation needed]}, although it is not covered under the VA benefits package as of August 2012.^[3]

[edit] Pharmacology

Asenapine shows high affinity (pKi) for numerous receptors, including the serotonin 5-HT_1A (8.6), 5-HT_1B (8.4), 5-HT_2A (10.2), 5-HT_2B (9.8), 5-HT_2C (10.5), 5-HT_5A (8.8), 5-HT₆ (9.5), and 5-HT₇ (9.9) receptors, the adrenergic α₁ (8.9), α_2A (8.9), α_2B (9.5), and α_2C (8.9) receptors, the dopamine D₁ (8.9), D₂ (8.9), D₃ (9.4), and D₄ (9.0) receptors, and the histamine H₁ (9.0) and H₂ (8.2) receptors. It has much lower affinity (pKi < 5) for the muscarinic acetylcholine receptors. Asenapine behaves as a partial agonist at the 5-HT_1A receptors.^[4] At all other targets Asenapine is an antagonist.^[5] As of November 2010 Asenapine is also in clinical trials at UC Irvine to treat stuttering.

Receptor	Affinity (pK_i)^[5]	Affinity (K_i (nM))^[6]
5-HT_1A	8.6	2.5
5-HT_1B	8.4	4.0
5-HT_2A	10.2	0.06
5-HT_2B	9.8	0.16
5-HT_2C	10.5	0.03
5-HT_5A	8.8	1.6
5-HT₆	9.5	0.25
5-HT₇	9.9	0.13
α₁-Adrenergic	8.9	1.2
α_2A-Adrenergic	8.9	1.2
α_2B-Adrenergic	9.5	? (~0.25)
α_2C-Adrenergic	8.9	1.2
D₁	8.9	1.4
D₂	8.9	1.3
D₃	9.4	0.42
D₄	9.0	1.1
H₁	9.0	1.0
H₂	8.2	6.2
mACh	< 5	8,128

[edit] Indications and usage

Asenapine has been approved by the FDA for the acute treatment of adults with schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.^[6]

[edit] Side effects

Common side effects: (incidence at least 5% or greater and at least twice that for placebo or greater than 10% regardless of placebo rate) Akathisia, oral hypoesthesia, somnolence, dizziness, extrapyramidal symptoms other than akathisia, weight gain, sedation, insomnia, headache.

Rare side effects: Neuroleptic malignant syndrome (Combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness, and sudden change in blood pressure and heart rate.), tardive dyskinesia.

The FDA has warned healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris. Healthcare professionals and patients are encouraged to report adverse events or side effects to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.^[7]

[edit] Synthesis

J. van der Burg, U.S. Patent 4,145,434.

Reduction step is sodium in liquid ammonia.

[edit] References

^ "Bipolar Disorder". Clinical Trials Update (Genetic Engineering & Biotechnology News). 2007-06-15. pp. 52,55. |accessdate= requires |url= (help)
^ "Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA" (Press release). Schering-Plough. 2007-11-26. Retrieved 2008-12-29.
^ "National Formulary". Unites States Department of Veterans Affairs. Retrieved 24 August 2012.
^ http://cat.inist.fr/?aModele=afficheN&cpsidt=21237275
^ ^a ^b Shahid M, Walker GB, Zorn SH, Wong EH. (2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.". J Psychopharmacol. 23 (1): 65–73. doi:10.1177/0269881107082944. PMID 18308814.
^ ^a ^b "Saphris (asenapine) prescribing information" (PDF). Schering Corporation. 2009-08-01. Retrieved 2009-09-05.
^ http://www.drugs.com/fda/saphris-asenapine-maleate-safety-communication-serious-allergic-reactions-13022.html

[edit] External links

[GEN200706-1] "Bipolar Disorder". Clinical Trials Update (Genetic Engineering & Biotechnology News). 2007-06-15. pp. 52,55. |accessdate= requires |url= (help)

[2] "Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA" (Press release). Schering-Plough. 2007-11-26. Retrieved 2008-12-29.

[3] "National Formulary". Unites States Department of Veterans Affairs. Retrieved 24 August 2012.

[4] ttp://cat.inist.fr/?aModele=afficheN&cpsidt=21237275

[pmid18308814-5] Shahid M, Walker GB, Zorn SH, Wong EH. (2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.". J Psychopharmacol. 23 (1): 65–73. doi:10.1177/0269881107082944. PMID 18308814.

[asenapinepi-6] "Saphris (asenapine) prescribing information" (PDF). Schering Corporation. 2009-08-01. Retrieved 2009-09-05.

[7] ttp://www.drugs.com/fda/saphris-asenapine-maleate-safety-communication-serious-allergic-reactions-13022.html

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Asenapine

Contents

[edit] Pharmacology

[edit] Indications and usage

[edit] Side effects

[edit] Synthesis

[edit] References

[edit] External links

Navigation menu

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Interaction

Toolbox

Print/export

Languages



Systematic (IUPAC) name
(3aRS,12bRS)-rel-5-Chloro-2,3,3a,12b-tetrahydro- 2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
Clinical data
Trade names	Saphris, Sycrest
AHFS/Drugs.com	monograph
MedlinePlus	a610015
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	C (US)
Legal status	Rx only
Routes	sublingual
Pharmacokinetic data
Bioavailability	35% sublingual
Protein binding	95%
Metabolism	hepatic
Half-life	24 hours
Excretion	50% in urine, 40% in feces
Identifiers
CAS number	65576-45-6^N
ATC code	N05AH05
PubChem	CID 163091
IUPHAR ligand	22
ChemSpider	2300725^Y
UNII	JKZ19V908O^Y
ChEBI	CHEBI:71253^Y
ChEMBL	CHEMBL1201756^N
Chemical data
Formula	C₁₇H₁₆Cl N O
Mol. mass	285.77 g/mol
SMILES Clc4cc2c(Oc1c(cccc1)[C@@H]3CN(C[C@@H]23)C)cc4
InChI InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1^Y Key:VSWBSWWIRNCQIJ-GJZGRUSLSA-N^Y
N (what is this?) (verify)